a n a ly s i s Cancers exhibit extensive mutational heterogeneity, and the resulting long-tail phenomenon complicates the discovery of genes and pathways that are significantly mutated in cancer. We perform a pan-cancer analysis of mutated networks in 3,281 samples from 12 cancer types from The Cancer Genome Atlas (TCGA) using HotNet2, a new algorithm to find mutated subnetworks that overcomes the limitations of existing single-gene, pathway and network approaches. We identify 16 significantly mutated subnetworks that comprise well-known cancer signaling pathways as well as subnetworks with less characterized roles in cancer, including cohesin, condensin and others. Many of these subnetworks exhibit co-occurring mutations across samples. These subnetworks contain dozens of genes with rare somatic mutations across multiple cancers; many of these genes have additional evidence supporting a role in cancer. By illuminating these rare combinations of mutations, pan-cancer network analyses provide a roadmap to investigate new diagnostic and therapeutic opportunities across cancer types.
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Recent whole-genome and whole-exome sequencing studies have provided an ever-expanding survey of somatic aberrations in cancer and have identified multiple new cancer-related genes [1] [2] [3] [4] [5] [6] [7] . At the same time, these studies demonstrated that most cancers exhibit extensive mutational heterogeneity, with few significantly mutated genes and many genes mutated in a small number of samples [8] [9] [10] . This 'long-tail' phenomenon complicates efforts to identify cancer-related genes by statistical tests of mutational recurrence, as rarely mutated cancer genes may be indistinguishable from genes containing only passenger mutations. Even recent TCGA pan-cancer studies [11] [12] [13] [14] [15] [16] had limited power to characterize genes in the long tail, leaving an incomplete picture of the functional, somatic mutations in these samples.
A prominent explanation for the mutational heterogeneity observed in cancer is the fact that genes act together in various signaling and regulatory pathways and protein complexes 9, 15 . Clustering of mutations in known pathways has been illustrated in previous TCGA studies 1-6 but typically without a measure of statistical significance. Although statistical tests of enrichment in known pathways or gene sets exist, such tests do not identify new pathways, have limited power to evaluate cross-talk between known pathways and generally ignore the topology of interactions between genes.
We introduce a new and complementary approach to identify pathways and protein complexes perturbed by somatic aberrations. This approach combines (i) a new algorithm, HotNet2, for the identification of mutated subnetworks in a genome-scale interaction network and (ii) a large TCGA pan-cancer data set of somatic single-nucleotide variants (SNVs), small indels and copy number aberrations (CNAs) measured in 3,281 samples from 12 cancer types 14 . HotNet2 uses a directed heat diffusion model to simultaneously assess the significance of mutations in individual genes and the local topology of interactions among the encoded proteins, overcoming the limitations of pathway-based enrichment statistics and earlier network approaches.
Our TCGA HotNet2 pan-cancer analysis identifies 16 significantly mutated subnetworks that encompass classic cancer signaling pathways, pathways and complexes with more recently characterized roles in cancer, and protein complexes and groups of interacting proteins with less characterized roles in cancer, such as the cohesin and condensin complexes. These latter two subnetworks-as well as many of the proteins in all subnetworks-are rarely affected by mutations in each cancer type and were thus identified only by the pan-cancer network analysis. Many of the rarely mutated proteins in a n a ly s i s the subnetworks have documented physical interactions with wellcharacterized cancer-related proteins and/or mutational patterns (for example, clustering in protein sequences or structures or an excess of inactivating alterations) that lend additional support for their role in cancer. Co-occurrence of alterations across these subnetworks supports the hypothesis that many of the subnetworks correspond to distinct biological functions.
In comparison to single-gene tests of significance, our TCGA HotNet2 pan-cancer analysis delves deeper into the long tail of rarely mutated genes and also assembles combinations of individual genes into a relatively small number of interacting networks. The mutational landscape of cancer has been proposed to consist of 'mountains' of frequently mutated genes and 'hills' of less frequently mutated genes 9 . Our pan-cancer network approach provides a richer annotation of this landscape, grouping individual peaks and mountains into mountain ranges and their associated foothills, further enabling diagnostic and therapeutic approaches in cancer care.
RESULTS

HotNet2 identifies significantly mutated subnetworks
We assembled a TCGA pan-cancer data set of exome sequencing, array copy number and RNA sequencing (RNA-seq) data from 3,281 samples from 12 cancer types, analyzing SNVs, small indels and CNAs in 19,424 transcripts ( Fig. 1a and Supplementary Fig. 1 ). After we removed hypermutated samples and genes with low expression in all tumor types (Online Methods), the data set contained 11,565 mutated genes in 3,110 tumors. We observed that the number of samples with a mutation in a given gene varied over three orders of magnitude, with from 1 to 1,291 mutated samples (Fig. 1b) . Moreover, we discovered that this broad spectrum of mutational frequencies-from common to extremely rare-posed a challenge for the identification of significantly mutated subnetworks. Specifically, our goal was to identify subnetworks according to both the frequency of somatic mutations in individual genes and the topology of the interactions between the corresponding proteins. However, the presence of highly mutated genes encoding highly connected proteins such as TP53 presents difficulties for existing algorithms that attempt to achieve this goal, for example, the HotNet algorithm 16, 17 that was used for cancer network analysis in TCGA and other studies 3, 4, 7, 18 and related network-propagation approaches 19 . In the heat diffusion model used in HotNet, genes such as TP53 are extremely 'hot' nodes and propagate this heat to their neighboring nodes. The resulting 'star' subnetworks centered on the hot node (Online Methods and Supplementary Fig. 2 ) contain many neighboring genes that are not mutated at an appreciable frequency and are of limited biological interest.
We introduce the HotNet2 (HotNet diffusion-oriented subnetworks) algorithm to address the problem of finding significantly mutated subnetworks in large, broad data sets of mutational frequency spectra such as the pan-cancer data (Fig. 1c,d and Supplementary  Fig. 3 ). HotNet2 uses a modified diffusion process and considers the source, or directionality, of heat flow in the identification of subnetworks ( Supplementary Fig. 4 ). This approach reduces the incidence of the artifact of star subnetworks by more than 80%, decreasing the false positive rate and enabling the identification of more subtle subnetworks with rare mutations of high biological relevance (Online Methods). We compared HotNet2 to other algorithms (Online Methods) and found that HotNet2 has higher sensitivity and specificity on both real and simulated data.
We performed HotNet2 analysis using two approaches to assign heat to individual genes according to mutational recurrence 20 and using three different interaction networks [21] [22] [23] [24] with varying numbers of interactions (Online Methods). HotNet2 identified a significant number of subnetworks (P < 0.01; Supplementary Tables 1 and 2) for each of the two gene scores and three networks. We combined the resulting subnetworks into 14 consensus subnetworks that were found across different gene scores and networks (P < 0.004 ; Supplementary  Tables 3-5) , plus the condensin complex and a network containing the CLASP and CLIP proteins (Supplementary Fig. 5 ) that were significant in individual interaction networks (Supplementary Tables 6 and 7) . Our consensus process also identified 13 'linker' proteins that were members of more than one consensus subnetwork. We developed an online interactive viewer for the HotNet2 pan-cancer subnetworks (see URLs and Supplementary Fig. 6 ).
The subnetworks and linker genes (Fig. 2a) included portions of well-known cancer pathways such as the TP53, phosphoinositide 3-kinase (PI3K), NOTCH and receptor tyrosine kinases (RTK) signaling pathways ( Supplementary Fig. 7) , as well as pathways and complexes that have more recently been observed to be important in cancer, such as the SWI/SNF and BAP1 chromatin-remodeling complexes, NFE2L2-KEAP1 ( Supplementary Figs. 8 and 9 ) and the RUNX1-CBFB core binding complex (Supplementary Fig. 10 ). The fifth most mutated subnetwork (16.9% of samples) consisted of MLL2 and MLL3 and the putative interacting protein KDM6A (Supplementary Fig. 11 ) and was highly mutated (28.9% of samples) in the TCGA pan-cancer squamous integrated subtype 25 . HotNet2 identified less characterized and potentially new subnetworks that might also have important roles in cancer, including the cohesin and condensin complexes and major histocompatibility complex (MHC) class I proteins. The MHC class I subnetwork (Supplementary Fig. 12 ) exemplifies the ability of HotNet2 to identify rarely mutated cancer-related genes: all of the genes constituting the subnetwork were mutated in fewer than 35 samples (1.1%), yet 4 of the 5 genes have recently been proposed as new cancer-relevant genes 11 . The sections below further detail a subset of these subnetworks. Additional analyses are provided in the Supplementary Note.
Many of the subnetworks exhibited a significant enrichment for mutations in a subset of cancer types, including many previously unreported associations (Supplementary Tables 6-18 ). We also identified genes within these subnetworks enriched for mutations in particular cancer types. In addition, the HotNet2 pan-cancer analysis provided a clearer and more robust summary of subnetworks and newly involved genes than HotNet2 analysis of individual cancer types (Supplementary Table 19 ).
These subnetworks and linkers included a total of 147 genes, with many well-known cancer genes and pathways but also genes with mutations that were too rare to be significant by single-gene tests (Supplementary Table 20 9 , and an additional 13 genes were reported in only one such list. Many of these genes have literature evidence supporting a potential role in cancer, and others are in biological processes that suggest that these genes warrant further study. A subset of the promising candidates is listed in Table 1 , with the full list and associated references appearing in Supplementary Table 20 .
To obtain additional support for these genes, we examined whether they had either an excess of inactivating mutations 9 or a cluster of missense mutations in the encoded protein sequence (using NMC 30 ) or structure (using iPAC 31 ; Supplementary Figs. 13 and 14 , and Supplementary Tables 21 and 22). We found that the genes in HotNet2 consensus subnetworks were enriched for inactivating npg a n a ly s i s mutations (P < 0.0001) or mutation clusters (P < 0.0001) in comparison to genes not in subnetworks (Supplementary Tables 6-18 and Supplementary Note). Finally, we evaluated a subset of the mutations in these genes using RNA-seq and whole-genome sequencing data from the same samples and found RNA-seq and/or wholegenome sequencing reads that validated 39 mutations in these genes (Supplementary Table 23 and Supplementary Note). These genes might represent new biomarkers for the classification of patients for treatment regimens.
Co-occurrence and mutual exclusivity of mutations in subnetworks
Cancer cells are thought to harbor multiple driver mutations that perturb multiple biological functions 15 . Consistent with this model, we found that four pairs of subnetworks, including TP53 and NOTCH signaling, TP53 and RTK signaling, PI3K signaling and the cohesin complex, and PI3K signaling and the ASCOM complex, exhibited significant co-occurrence (P < 0.05, multiple-hypotheses corrected) across the pan-cancer cohort (Fig. 2b) or in individual cancer types (Fig. 2c) . Multiple pairs of genes within these subnetworks showed co-occurring mutations (Supplementary Table 24 ). In contrast, mutually exclusive mutations are typically expected within a pathway and not across pathways 32, 33 . We observed significant mutual exclusivity within four of our subnetworks (Supplementary Table 25) . Intriguingly, the RTK signaling and NFE2L2-KEAP1 subnetworks were the only pair with significant mutual exclusivity across the pan-cancer cohort. This mutual exclusivity was largely due to lung adenocarcinoma (LUAD) samples with mutually exclusive EGFR and KEAP1 mutations (Supplementary Fig. 15 ). This observation is consistent with reports of mutual exclusivity between EGFR mutations and NFE2L2 expression in LUAD 34 and also with NFE2L2 expression being downstream of EGFR signaling 35 . Examining individual cancers, we found a modest but not statistically significant enrichment for co-occurrence or mutual exclusivity in a few cancer types (Supplementary Table 26 ). Neither within-subnetwork mutual exclusivity nor across-subnetwork co-occurrence is explicitly programmed into the HotNet2 algorithm. These observations support the hypothesis that the HotNet2 subnetworks represent distinct biological functions that are mutated in samples.
TP53, PIK3CA and NOTCH networks
The three largest subnetworks-including a TP53 subnetwork, a PIK3CA subnetwork and a NOTCH subnetwork-contained many well-known cancer-related genes ( Supplementary Figs. 16 and 17, and Supplementary Tables 8-10 ). Linker genes joined these three subnetworks, demonstrating the extensive cross-talk between wellannotated cancer pathways. Most of these linker genes encoded signaling proteins that have known cancer-related functions (for example, WT1, NOTCH2, PIK3R1, MAP2K4, MAP3K1, HRAS, ATM and STK11). Taken together, 81.9% of the samples contained at least one mutation in these three large subnetworks and linker genes.
HotNet2 pan-cancer analyses also identified a number of newly involved genes (Supplementary Table 20 ) within these three subnetworks. These genes have documented interactions with well-known cancer-relevant genes and similar functions but with somewhat lower mutational frequency (~1%) and were not marked as significant by single-gene tests 20, [26] [27] [28] [29] . For example, the TP53 subnetwork included CUL9. CUL9 sequesters p53 in the cytoplasm, and we found a cluster of 45 missense mutations (P = 1.32 × 10 −8 ) as well as a cluster in the protein structure (false discovery rate (FDR) = 0.025). Another gene of interest was IWS1, which is involved in transcriptional elongation and mRNA surveillance. Half (8/16) of the mutations in this gene were inactivating, and this gene also had a cluster of mutations (P = 0.013). This subnetwork also contained CHD8, encoding an ATPdependent chromatin-remodeling factor that regulates a wide range of genes 36 . We found three independent signals of CHD8 inactivation across samples: CHD8 was deleted in 9 samples in a focal peak from GISTIC; 18 of 58 (31%) of its mutations were inactivating; and this gene had a wide cluster of missense mutations (P = 6.37 × 10 −5 ). npg a n a ly s i s
In the NOTCH subnetwork, we found rare mutations in JAG1 and DLL1, whose gene products interact with the NOTCH receptors and have some reports of a role in cancer 37 . Moreover, 11 of 24 mutations in JAG1 were inactivating. The NOTCH subnetwork also included SHPRH, which had a significant (P < 8 × 10 −5 ) cluster of missense mutations ( Supplementary Fig. 18 ).
SWI/SNF complex
The sixth most mutated HotNet2 pan-cancer subnetwork (16.8% of samples) included multiple members of the SWI/SNF chromatin-remodeling complex ( Fig. 3a and Supplementary Table 12) . Mutations in this complex have previously been reported in several cancers 38, 39 , including TCGA samples 40 . Our HotNet2 pan-cancer analysis demonstrated the prevalence of mutations in SWI/SNF components: at least 1.5% of the samples from each of the 12 cancer types contained a mutation in this subnetwork. Kidney renal clear cell carcinoma (KIRC) (P < 1 × 10 −15 ), uterine corpus endometrial carcinoma (UCEC) (P = 7 × 10 −10 ) and bladder urothelial carcinoma (BLCA) (P = 1.8 × 10 −8 ) were enriched for mutations in this subnetwork, and several genes were enriched for mutations in specific cancer types, including PBRM1 in KIRC (P < 1 × 10 −15 ) and ARID1A in both BLCA (P = 4.8 × 10 −8 ) and UCEC (P < 1 × 10 −15 ). The subnetwork also contained ARID1B, which has been reported to have somatic mutations in juvenile neuroblastoma 41 and germline mutations in Coffin-Siris syndrome 42 .
In addition to known members of the SWI/SNF complex, the subnetwork included ADNP. ADNP mutations have not previously been reported in cancer and were not considered significant by the three individual gene-scoring methods applied. However, ADNP has a known interaction with the SWI/SNF complex 43 and protects against oxidative stress in neuronal cells 44 (a) HotNet2 consensus subnetworks are arranged near the cancer types where they are enriched for mutations using a force-directed layout (BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COADREAD, colon adenocarcinoma and rectum adenocarcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LAML, acute myeloid leukemia; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; UCEC, uterine corpus endometrioid carcinoma). Colored outlines surrounding each network indicate the cancer types that are enriched for mutations (corrected P < 0.05). Interactions between proteins in a subnetwork are derived from the three interaction networks used in our pan-cancer analysis. In the center, there are 13 linkers that are members of more than one consensus subnetwork; lines between linkers and other consensus subnetworks indicate protein-protein interactions between them. Genes with a single asterisk were significant by exactly one of GISTIC2, MuSiC, MutSigCV, Oncodrive or the list of driver genes in ref. 9 , whereas genes with two asterisks were not reported by any of these methods. (b) Heat map of significant co-occurrence (yellow; lower triangle) and mutual exclusivity (blue; upper triangle) of mutations across all pan-cancer samples in the most frequently mutated HotNet2 pan-cancer consensus and condensin subnetworks (P < 0.01, Cochran-Mantel-Haenszel test). Black outlines indicate pairs of subnetworks that have P < 0.05 after multiple-hypothesis correction. (c) Mutual exclusivity and co-occurrence (P < 0.01, Fisher's exact test) within individual cancer types using the same color scheme as in a. npg a n a ly s i s analyses broaden the view of mutations in the SWI/SNF complex to additional cancer types and additional interacting proteins.
BAP1 complex and interactors
Another HotNet2 pan-cancer subnetwork (mutated in 7.1% of samples) overlapped the BAP1 complex ( Fig. 3b and Supplementary Table 13 ). This subnetwork included BAP1, ASXL1, ASXL2, FOXK1 and FOXK2, all encoding members of the BAP1 core complex 45 , as well as two additional interacting factors, KDM1B and ANKRD17. Only BAP1 and ASXL1 were significant by individual-gene scores-the other genes harbored rare mutations across many cancer types, a subtle signal identified by HotNet2 pan-cancer analysis. This subnetwork was mutated in at least six samples from each cancer type, demonstrating the breadth of mutations in the BAP1 complex.
BAP1 inactivation has been reported in several cancers 45 . We found the subnetwork enriched for mutations in KIRC (P = 2 × 10 −4 ), as previously reported 46 . Consistent with the results of Peña-Llopis et al. 46 , we found that mutations in the BAP1 gene were mutually exclusive (P < 7.2 × 10 −3 ) with mutations in the PBRM1 gene in KIRC. We found that mutations in the SWI/SNF and BAP1 complexes showed even greater mutual exclusivity (P = 9.4 × 10 −5 ) in KIRC because of mutations in additional genes in these complexes in addition to BAP1 and PBRM1, respectively (Supplementary Note). This mutual exclusivity suggests that mutations in these complexes define different subtypes of kidney cancer. Supporting this hypothesis, we observed that inactivating mutations in the BAP1 complex were enriched (P < 3.4 × 10 −8 ) for samples in the third mRNA expression subtype described in ref. 3 (Fig. 3c) .
We found that a large fraction of the mutations in BAP1, ASXL1 and ASXL2 in different cancer types were inactivating mutations, demonstrating alternative strategies for the inactivation of the BAP1 complex. In addition, 6 of 13 missense mutations in FOXK2 affected the forkhead transcription factor domain or forkhead-associated domain, which might inactivate the DNA-binding properties of FOXK2. Finally, we examined the mutations in KDM1B, which encodes a protein that is involved in histone H3 lysine 4 (H3K4) methylation 47 but is not considered to be a core part of the BAP1 complex. We found that 12 of 19 mutations in KDM1B (including 10 of 16 missense mutations) fell in the C-terminal amino-oxidase domain that is important for lysine-specific demethylation of histones 48 . Moreover, two of the three KDM1B mutations in lung squamous cell carcinoma (LUSC) and LUAD were inactivating, and these were also mutually exclusive with BAP1 inactivating mutations, suggesting that KDM1B mutations might have a role in cancer.
Cohesin and condensin
HotNet2 pan-cancer analysis identified four of five members of the cohesin complex as a significantly mutated subnetwork (7.3% of samples; Fig. 4a and Supplementary Table 15) . Although named for its role in sister chromatid cohesion, the cohesin complex has recently been implicated more broadly in gene regulation [49] [50] [51] , and its role in myeloid leukemia was only recently reported 52 . We found that the cohesin complex was universally mutated across cancer types (>4% of samples in each cancer type). Moreover, the mutations in the complex were spread uniformly across the genes, with no gene in the complex mutated in more than 1.9% of samples. This pattern For each gene, the number of samples with at least one SNV or CNA in the gene and the cancers enriched for mutations (P < 0.05, corrected) are listed. More information on these genes as well as other candidate driver genes is provided in supplementary Table 20 .
a Listed as a cancer driver by Oncodrive or GISTIC.
npg a n a ly s i s N80Y  E226Q  I245F  I252R  P427S  N453S  F456S  R522L  M523R  N528I  Y580C  E583K  M586K  M586I  M586T  N601K  L614V  L618H  G626V  I709T  Y718C  M731K  R760H  E860K  R876L  P1048L  P1048R  R1088Q  V1136L  T1202K  G1231R  C1233W  E1248G  E1287D  I1309T  D1325N  R1411C  W1417G  M1539I  G1554R  G1577C  L1611P  R1670P Figure 3 HotNet2 pan-cancer subnetworks overlapping SWI/SNF and BAP1 complexes. (a) Subnetwork containing members of the SWI/SNF complex, including the BAF proteins ARID1A and ARID1B, the PBAF proteins PBRM1 and ARID2, the catalytic core member SMARCA4, SMARCB1 and ADNP. (a) Top, mutation matrix showing the samples (colored by cancer type) with a mutation of the indicated type: full ticks represent SNVs, indels and splice-site mutations; upticks and downticks represent amplifications and deletions, respectively. A black dot corresponds to samples with an inactivating mutation in the gene and indicates that the genes contain at least one of the following mutations: nonsense, frameshift indel, nonstop or splice site. The number of samples with mutations in a gene is given in parentheses; marks are defined as in Figure 2a . Bottom left, interactions between proteins in the subnetwork from each interaction network are colored according to mutually enriched cancer type with corresponding P values. PPI, protein-protein interaction. Bottom right, the PBRM1 protein sequence exhibited significant clustering of missense alterations (P = 1.6 × 10 −5 ) in a 105-amino-acid bromodomain, a region that was reported to be mutated in a different renal clear cell carcinoma cohort 39 but not in the TCGA KIRC publication 3 . Splice-site mutations are annotated with the nearest exon, where +1 and +2 refer to the adjacent 3′ splice donor and −1 and −2 refer to the adjacent 5′ splice acceptor. (b) Subnetwork containing members of the BAP1 complex, including the core PR-DUB complex, comprised of the deubiquitinating enzyme BAP1 and the Polycomb group proteins ASXL1 and ASXL2, as well as the BAP1-interacting proteins: ANKRD17, FOXK1, FOXK2 and KDM1B. Colors, marks and panel organization are as in a. (c) Inactivating mutations across samples (columns) in the SWI/SNF and BAP1 complexes (rows) in KIRC. The bottom row shows the mRNA expression classification of each sample 3 . The mutations in these complexes are surprisingly mutually exclusive in KIRC (P < 3.6 × 10 −4 , Fisher's exact test, corrected), and the BAP1 complex is significantly enriched in mutations in the third expression subtype (P < 3.4 × 10 −8 , Fisher's exact test). npg a n a ly s i s of mutations complicates the identification of recurrent mutations in individual genes; indeed, only half of the genes in the complex (STAG2, SMC1A and RAD21) were significant by at least one of the three gene scores applied.
Mutations in some of these genes have recently been reported to be significant in several cancers. We found enrichment for mutations in the subnetwork in BLCA (P = 7 × 10 −4 ); this enrichment derived largely from enrichment for mutations in STAG2 in BLCA (P = 0.005), which was recently reported 53 . STAG2 had a significantly higher fraction of inactivating mutations than other genes in the subnetwork (53% for STAG2 in comparison to 28% for the subnetwork as a whole); these inactivating mutations were not only in BLCA but also across multiple cancer types, with multiple inactivating mutations in acute myeloid leukemia (LAML) and colon and rectal adenocarcinoma (COADREAD). In addition, BLCA samples without STAG2 inactivating mutations harbored rare inactivating mutations in several other cohesin genes. All mutations in RAD21 in LAML samples were inactivating, and BRCA and KIRC samples harbored inactivating mutations in STAG1. In addition, we observed a significant clustering of missense mutations in STAG1 (P = 6 × 10 −5 ), and the broad span of the cluster (135 residues) is indicative of inactivation. STAG1 has been shown to function as a transcriptional coactivator 50, 51 , and mutation of STAG1 might thus have another role in cancer apart from affecting genome stability. Together, these results show that mutational inactivation of the cohesin complex occurs broadly across cancer types and across genes within the complex.
HotNet2 also identified two subnetworks containing six proteins in the condensin complex, in HotNet2 runs from individual interaction networks. The combined subnetwork was mutated in 4.2% of samples ( Fig. 4b and Supplementary Table 6 ). Only SMC4 was reported to be significant by at least one of the individual-gene scores. A subnetwork consisting of NCAPD2, SMC2 and SMC4, all members of the condensin I form of the complex, was significantly mutated in BLCA (P = 6.2 × 10 −6 ). Condensin I is thought to primarily be involved in sister chromatid condensation during mitosis 54, 55 , suggesting that these mutations promote genome instability. In contrast, a subnetwork consisting of NCAPD3, NCAPG2 and NCAPH2, all members of the condensin II form of the complex, was significantly mutated in LUAD (P = 0.04) and LUSC (P = 0.002), and the majority (4/7) of NCAPG2 mutations in LUSC were inactivating. Condensin II is generally involved in gene regulatory processes 54, 55 , suggesting a different phenotype for these mutations. In addition, we found a significant (P = 0.002) cluster of missense mutations in NCAPH2 (Fig. 4b) , implying that mutations in this region of unknown function might be important for the deregulation of condensin. We also note that it was recently observed that expression of NCAPD3 is positively associated with recurrence-free survival 56 . Finally, RNAseq and whole-genome sequencing data from the same samples provided further validation of the somatic mutations in SMC2, SMC4, NCAPD2, NCAPD3, NCAPH2 and NCAPG2 and showed that some of these mutations were expressed (Supplementary Table 23 and Supplementary Note). Our HotNet2 pan-cancer analysis suggests that multiple cancer types harbor rare mutations in the cohesin and condensin complexes, supporting a proposed tumor-suppressor role for these complexes 49, 54, 55 . Figure 4 HotNet2 pan-cancer subnetworks overlapping the cohesin and condensin complexes. (a) Cohesin consensus subnetwork and its mutations. Colors and marks are as defined in Figure 3a . None of the genes are mutated in more than 1.9% of the samples, but the subnetwork is mutated in >4% of the samples in each cancer type. STAG1 exhibits significant (P < 6 × 10 −5 ) clustering of missense alterations across 135 residues (highlighted) in the Pfam-B domain (PFAM, PB002581), a pattern suggesting inactivation of the corresponding domain. (b) Condensin consensus subnetwork and its mutations. Top, mutation matrix showing five genes in the condensin I and condensin II complexes. Only one gene, SMC4, was significant by individual gene scores. Bottom left, a subnetwork consisting of NCAPD2 and SMC4, both members of condensin I, was significantly mutated in BLCA, and a subnetwork consisting of NCAPD3, NCAPG2 and NCAPH2, all members of condensin II, was significantly mutated in LUAD and LUSC. At the gene level, NCAPD2 was significantly mutated in BLCA, SMC4 was significantly mutated in BLCA and HNSC, NCAPD3 was significantly mutated in LUAD and NCAPG2 was significantly mutated in LUSC. Bottom right, NCAPH2 shows a significant (P < 2.6 × 10 −4 ) cluster of missense alterations between Arg551 and Ser556. npg a n a ly s i s many classic cancer pathways, such as TP53, PI3K, NOTCH and RTK signaling, automatically from a large-scale interaction network, demonstrating the power of the pan-cancer network approach. Second, we highlight the extensive cross-talk between these pathways, overlaps that are often overlooked in analyses that treat pathways as distinct gene lists. Third, we find pathways and complexes whose role in cancer has only recently been appreciated, such as the SWI/SNF chromatin-remodeling complex 38 and the BAP1 complex 45 . Fourth, we find that several pairs of HotNet2 subnetworks have co-occurring mutations, although mutations are mostly mutually exclusive within subnetworks. This finding supports the hypothesis that these subnetworks represent distinct biological functions that are mutated in samples. Finally, we identify a number of new mutated subnetworks with potential roles in cancer, including the cohesin and condensin complexes 54 , MHC class I proteins and the telomerase complex. These subnetworks have rare mutations in nearly all cancer types, making them difficult to detect without a sensitive pan-cancer network approach that examines combinations of genes across multiple cancer types. The HotNet2 subnetworks contain 92 genes that are rarely mutated, both in individual cancer types and across the pan-cancer cohort, and are not reported as significant by single-gene tests. Nearly all of the subnetworks contain such genes, which are identified by the combination of their mutations and interactions across cancer types. Some of these rarely mutated genes are inevitably false positive predictions of the analysis, but many (including SHPRH, CUL9, CHD8, RNF20, JAG1, ELF3, STAG1, NCAPH2 and others) exhibit either mutational clustering or protein interactions that support a role for the observed somatic aberrations in cancer (Supplementary Tables 6-18 ). In addition, we find that well-characterized mutations in a single gene in one cancer type (for example, inactivating mutations in BAP1 in KIRC) are replaced in other cancer types by rare mutations in other members of the same complex (for example, inactivating mutations in ASXL1, ASXL2, FOXK2 and KDM1B). Such observations suggest that pan-cancer network analyses might prove useful in translating diagnostic or therapeutic approaches that were developed in one cancer type to other cancer types.
DISCUSSION
Our analysis complements other recent pan-cancer analyses, including studies that analyzed only one type of aberration [11] [12] [13] or restricted their focus to recurrent aberrations 57 (Supplementary  Table 27 and Supplementary Note). The HotNet2 pan-cancer network approach identifies combinations of rare and common mutations in groups of interacting genes-combinations that were not apparent by the analysis of single genes, known pathways or single cancer types. Indeed, we observe that many of the identified subnetworks contain genes altered by both SNVs and CNAs, demonstrating that integrating data on multiple types of aberrations is beneficial when jointly analyzing multiple cancer types that might have different mutational landscapes. Pan-cancer network analysis of multiple aberration types thus provides an alternative approach to prioritize rare mutations for further experimental characterization.
As with any computational approach, our findings are limited by the quality and quantity of the input data. Further power is anticipated by including additional samples 11 , additional types of genetic and epigenetic aberrations, and better interaction networks. For example, structural variants, noncoding variants and methylation data were not included, with the first two being unavailable for most TCGA samples. This lack of data in combination with false negatives in the analyzed data (for example, due to difficulties in the identification of indels and subclonal variants) implies that our analysis likely underestimates the number and frequency of mutated subnetworks across cancer types. In contrast, we note that some genes that are highly significant by individual-gene scores are not reported in our network analysis; often this is owing to problems with the interaction network. Improved knowledge of the human interactomeincluding more systematic efforts to record known interactions, measure additional interactions and determine the tissue specificity of interactions-is needed to increase coverage and reduce possible ascertainment bias.
Finally, the HotNet2 algorithm introduced here is suitable for other applications, both biological and non-biological. In particular, genome-wide association studies (GWAS) and other studies of genetic diseases face an analogous problem in identifying combinations of genetic variants with a statistically significant association with a phenotype. With an appropriate gene score, the HotNet2 algorithm can be applied to such data.
URLs. HI2012 interactome, http://interactome.dfci.harvard.edu/; HotNet2 pan-cancer analysis website, http://compbio.cs.brown. edu/pancancer/hotnet2/; RNA expression data used for the TCGA pan-cancer data set, https://www.synapse.org/#!Synapse:syn1734155; pan-cancer mutations with additional germline variant filtering, https://www.synapse.org/#!Synapse:syn1729383; HotNet2 software release, http://compbio.cs.brown.edu/software.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Somatic aberration data. SNVs, indels and splice-site mutations were extracted from TCGA pan-cancer analysis on Synapse (syn1710680), and CNAs were extracted from GISTIC2 output via Firehose. We restricted our focus to the 3,276 samples containing both SNV and CNA data. We removed 71 samples identified as ultramutators in syn1729383 and an additional 95 samples with an unusually high number of aberrations (>400 SNVs or CNAs). We selected the threshold of 400 aberrations per sample, as the derivative of the number of mutations per sample starts increasing rapidly beyond this value (Supplementary Fig. 19 ). We removed genes without CNAs that contained SNVs in >2% of samples but were not identified as significant (q < 0.05) by MutSigCV 20 . Finally, we used only those genes that had at least three reads from RNA-seq data in at least 70% of samples of at least one of the cancer types, as described in syn1734155 (see URLs). The resulting data set contained aberrations in 11,565 genes and 3,110 samples (Supplementary Fig. 1 ). We used gene scores from mutation frequency and MutSigCV −log 10 q values. Nonsense mutations, frameshift indels, nonstop mutations or splice-site mutations were classified as inactivating according to ref. 12. We used three interaction networks: HINT+HI2012, a combination of the HINT network 21 24 . Additional details on the data sets are provided in the Supplementary Note.
HotNet2
. We developed the HotNet2 (HotNet diffusion-oriented subnetworks) algorithm to identify subnetworks of a genome-scale interaction network that were mutated more than expected by chance. Although interaction networks have proven useful in analyzing various types of genomic data 58 , statistically robust identification of significantly mutated subnetworks is a difficult problem with several major challenges (Supplementary Note). HotNet2 addresses these challenges and identifies significantly mutated subnetworks of a genome-scale interaction network, using an insulated heat diffusion process that considers both the scores on individual genes as well as the topology of interactions between the corresponding proteins (Supplementary Fig. 3) .
The input to HotNet2 is a heat vector  h that contains the score (for example, mutation frequency) for each gene g and a graph G = (V,E), where each node corresponds to a gene and each edge corresponds to an interaction between the encoded proteins. HotNet2 performs the following steps.
1. Heat diffusion. HotNet2 employs an insulated heat diffusion process 59,60 that captures the local topology of the interaction network surrounding a protein. At each time step, nodes in the graph pass to and receive heat from their neighbors but also retain a fraction β of their heat, governed by an insulating parameter β. The process is run until equilibrium is reached; the amount of heat on each node at equilibrium thus depends on the initial heat for the node, the local topology of the network around the node and the β value. If a unit heat source is placed at node j (for example, a mutation in g j in one sample), then the amount of heat on node i is given by the (i,j) entry of the diffusion matrix F defined by:
if node i interacts with node j, 0 otherwise. Thus, W is a normalized adjacency matrix of the graph G. We interpret F(i,j) as the influence that a heat source placed on g j has on g i . The insulated heat model can also be described in terms of a random walk with restart (Supplementary Note). Note that the insulated diffusion process is generally asymmetric, i.e., F(i,j) ≠ F(j,i). The diffusion matrix F depends only on the graph G and not on the heat vector  h. Therefore, the influence (for a given β) needs to be computed only once for a given interaction network.
2. Exchanged heat matrix. The insulated heat diffusion process described above encodes the local topology of the network, assuming that unit heat is placed on nodes. To jointly analyze the network topology and gene scores given by the initial heat vector h, we define the exchanged heat matrix E as:
 is the amount of heat that diffuses from node g j to node g i on the network when  h j ( ) heat is placed on g j , which we interpret as the similarity of g j ,g i .
As the diffusion matrix F is not symmetric and in general
3. Identification of hot subnetworks. We form a weighted directed graph H whose nodes are all measured genes. If E(i,j) > δ, then there is a directed edge from node j to node i of weight E(i,j). HotNet2 identifies strongly connected components in H. A strongly connected component C in a directed graph is a set of nodes such that for every pair u,v of nodes in C there is a path from u to v.
4. Statistical test for subnetworks. HotNet2 employs a statistical test to determine the significance of the number and size of the subnetworks determined in the previous step. The statistical test is the same as the two-stage statistical test introduced in the original HotNet algorithm 16, 17 ( Supplementary  Figs. 20-23, Supplementary Table 28 and Supplementary Note). HotNet2 is available online (see URLs).
HotNet2 parameters. HotNet2 has two parameters β and δ, and it selects values for both of these parameters using automated procedures. β is selected from the protein-protein interaction network, independently of any gene scores ( Supplementary Fig. 24, Supplementary Table 29 and Supplementary Note). We evaluated the sensitivity of the HotNet2 results to the value of β and found that varying β by ±10% had only a minor effect on the results, with at most seven genes (3.8% of the total) added or removed from the subnetworks (Supplementary Table 29 ). The value of δ is chosen such that large connected components are not found using the observed gene score distribution on random networks with the same degree distribution as the observed network ( Supplementary Fig. 25, Supplementary Table 30 and Supplementary Note). We evaluated the sensitivity of the HotNet2 results to the value of δ and found that varying δ by ±5% changed at most 35 genes (12.3% of the total) in the subnetworks (Supplementary Table 30) .
Comparison of HotNet2 to other algorithms. HotNet2 extends our previous algorithm HotNet 17, 18 in several directions. First, HotNet2 employs an insulated heat diffusion process that better encodes the local topology of the neighborhood surrounding a protein in the interaction network. Second, HotNet2 uses an asymmetric influence F(i,j) between two proteins g i and g j to derive a directed measure of similarity E(i,j) between them, whereas HotNet derives a symmetric influence. Third, HotNet2 identifies strongly connected components in the directed graph H, whereas HotNet computes connected components in an undirected graph. These differences enable HotNet2 to effectively detect significant subnetworks in data sets in which the number of samples is order(s) of magnitude larger than considered by HotNet and in which the mutational frequencies, or scores, occupy a broad range (from very common to extremely rare) (see Supplementary Fig. 2) .
Expanding on the third point, when undirected diffusion algorithms such as HotNet or related network-propagation algorithms 19 are run on large data sets containing a wide range of gene scores (for example, the pan-cancer data set), many of the resulting subnetworks are 'hot' star graphs determined by a single high-scoring node and the immediate neighbors of this node ( Supplementary  Fig. 2) . Star graphs or, more generally, spider graphs have one central node connected to multiple neighboring nodes that are not interconnected. Although the hot, center node in these star graphs is typically a significant gene, the neighboring nodes are often artifacts.
We found that HotNet2 returned >80% fewer hot stars/spiders than HotNet on the pan-cancer data sets (Supplementary Table 31 ). This is a major difference between the algorithms and is one of the reasons why HotNet fails to find statistically significant results (P ≤ 0.01 for any subnetwork size k) on three of six runs (Supplementary Tables 32 and 33) , whereas HotNet2 found statistically significant results on all six runs. The HotNet2 subnetworks also had a higher fraction of interactions with proteins other than a hot central node (Supplementary Note). These differences are explained by the undirected versus directed heat similarity measures used in HotNet versus HotNet2. We note that the goal of HotNet2 is not to eliminate hot stars/spiders but rather to reduce the number of such subnetworks that are false positives.
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We also compared HotNet2 to HotNet on simulated data. In short, the results show that HotNet2 achieves higher sensitivity and specificity than HotNet ( Supplementary Fig. 26 and Supplementary Note).
To further demonstrate the advantages of HotNet2 on the pan-cancer mutation frequency data set, we compared HotNet2 to HotNet and to two standard tests of pathway enrichment, DAVID 61, 62 and gene set enrichment analysis (GSEA) 63, 64 . We find that HotNet2 provides both new insights and a simpler summary of groups of interacting genes and is a useful complement (or arguably a replacement for) other pathway tests (Supplementary Note). We also show that HotNet2 has much higher specificity than HotNet, DAVID and GSEA in identifying genes satisfying the 20/20 rule 9 ( Supplementary Fig. 27,  Supplementary Tables 34-36 and Supplementary Note). Finally, we found that HotNet2 was more stable than HotNet in identifying 20/20 genes using cross-validation (Supplementary Fig. 28 and Supplementary Note) .
We attempted to compare HotNet2 to MEMo 65 , an algorithm to identify groups of interacting genes with mutually exclusive mutations. First, we note several important differences between HotNet2 and MEMo. Namely, HotNet2 (i) analyzes mutations and network topology simultaneously; (ii) is not restricted to analyzing mutually exclusive mutations and can analyze co-occurring mutations, and (iii) can use input heat scores that capture additional information (for example, functional relevance) about the mutations. We found that MEMo was unable to run on the pan-cancer mutation frequency data set, consistent with the authors' recommendation that MEMo should be run only on a small number of significant mutations (details provided in the Supplementary Note).
Finding consensus subnetworks and linkers. We ran HotNet2 on each combination of gene scores (mutation frequencies and MutSigCV 20 q values; Supplementary Note) and interaction networks (HINT+HI2012 (refs. 21, 22) , iRefIndex 23 and Multinet 24 ; Supplementary Fig. 29 and Supplementary Note). We derived 'consensus' subnetworks and 'linker' genes from the HotNet2 results on the different network and gene scores using an iterative procedure on a weighted graph. This procedure is described in the Supplementary Note.
We evaluated the statistical significance of the HotNet2 consensus subnetworks using the HotNet2 statistical test on consensus networks found in randomly permuted data. We generated the null distribution of consensus networks by permuting tuples containing the mutation frequency and MutSigCV score of genes over each of the networks. Thus, the permutation preserved the relationship between the mutation frequency and MutSigCV score. We then ran HotNet2 on the three networks using the permuted mutation frequency and MutSigCV score, forming a 'permuted consensus' using the same consensus procedure described above. We used these permuted consensus subnetworks to form an empirical distribution for the statistical test. Additional details of the statistical procedure are provided in the Supplementary Note. Expression and germline filtering. Most of the subnetworks (12/14) identified by HotNet2 were also found when we removed the requirement for RNA-seq expression (Supplementary Table 37 ). This result demonstrates the robustness and scalability of HotNet2, as the unfiltered mutation data included 19,459 genes. Notable among the additional subnetworks identified when we removed the requirement for RNA-seq expression was a subnetwork containing members of the telomerase complex (including TERT and TEP1) that has a well-studied role in cancer 66 ( Supplementary Fig. 30 and Supplementary  Table 38 ). Although the lack of RNA-seq reads from these genes is a concern, we note that the RNA-seq expression criteria were strict enough to exclude several bona fide cancer genes (see URLs). Thus, the lack of RNA-seq reads should not automatically exclude these genes from further study. We also ran HotNet2 using a more aggressive criterion to remove potential germline mutations (see URLs). We found only minor differences in the HotNet2 subnetworks (Supplementary Table 39) , demonstrating that our reported subnetworks are largely altered by somatic aberrations in these samples.
